Harbin Jixianglong Biotechnology Co., Ltd.

Harbin Jixianglong Biotechnology Co., Ltd. was established at the end of 2011 and is located in the Harbin Limin Development Zone. It covers an area of 23,000 square meters, 16,000 square meters of buildings, a registered capital of 18.31 million yuan, a net asset of 110 million yuan, and 260 employees (70 R&D). It is a national high-tech enterprise, Heilongjiang Specialized New SME and Synthetic Peptide Drug Technology Innovation Center. The company focuses on independent R&D and custom R&D and production of peptide drugs, forming a two-wheel drive pattern of peptide raw material sales and formulation R&D services (CRO). It has built a GMP-certified peptide raw material production workshop, equipped with more than 300 sets of equipment such as solid phase synthesizers, preparation liquid chromatography, lyophilizers, and HPLC. The company has a complete industrial chain of R&D, approval and production, and has obtained 10 API production approvals (the third in the country in terms of quantity) using its own technology; Smeglutide and Tirpotide have completed US DMF filings with the US FDA and obtained NDCs for sale in US pharmacies; it has 16 invention patents (including 5 compound patents).

Harbin Jixianglong Biotechnology Co., Ltd. is located at No. 99, Limin Development Zone Baoan Road, Hulan District, Harbin, China.

Main peptides produced: Epitalon, BPC-157, TB-500 (Thymosin Beta-4), DSIP.

Finished peptide dosage forms available (lyophilised powder for injection).

Website: https://www.hrbjxl.com